In this case, the injection went into one eyeball of a single person with glaucoma. The company did not share any other information about the patient. Over the next six months, scientists will be watching to see how well the technique works, while doctors keep an eye out for any safety issues.

To their credit, that’s a good test case - actual disease wifh significant impact.